| Year |
Auther |
Patients |
Borderline
N (%) |
Chemotherapy |
Radiation
(Gy) |
Resection rate N(%) |
R0 resection
N(%) |
Negative LN metastasis: N(%) |
Median overall
survival(M) |
| 2007 |
Palmer [7] |
24 |
- |
Gem |
- |
8(37.5%) |
6(75%) |
2(25%) |
9.9 |
| |
|
26 |
- |
Gem, Cis |
- |
18(69.2%) |
12(46.2%) |
7(44%) |
15.6 |
| 2008 |
Heinrich [8] |
28 |
- |
Gem, Cis |
- |
25(89.3%) |
20(80%) |
- |
19.1 |
| 2008 |
Varadhachary [18] |
90 |
- |
Gem, Cis |
30 |
52(58%) |
50(96.2%) |
20(38.5%) |
31 |
| 2009 |
Turrini [19] |
102 |
- |
5FU, Cis |
45 |
62(60.8%) |
57(91.9%) |
47(75.8%) |
23 |
| 2011 |
Patel [20] |
17 |
17(100%) |
Gem, TXT, Cap |
50 (5FU) |
9(64%) |
8(88.9%) |
- |
15.6 |
| 2011 |
Sahora [21] |
33 |
15(45.5%) |
Gem, Ox |
- |
13(39%) |
9(69.2%) |
4(30.8%) |
22 |
| 2012 |
Lee [22] |
43 |
18(41.9%) |
Gem, Cap |
- |
17(39.5%) |
14(82.4%) |
7(41.2%) |
23.1 |
| 2012 |
Hosein [23] |
18 |
4(23%) |
FOLFIRINOX |
- |
9(50%) |
8(88.9%) |
- |
- |
| |
This study |
11 |
5(45.5%) |
Gem, S1 |
- |
11(100%) |
10(90.9%) |
6(54.5%) |
- |
Abbreviations: LN- Lymph Node; Gem- Gemcitabine; Cis- Cisplatin; TXT- Docetaxel; Cap- Capecitabine; Ox- Oxaliplatin; M- Month |
